November 25, 2024

Retrospective Analysis of Rituximab Therapy for Myasthenia Gravis: A Case Series – Cureus

November 22, 2024

Self-injectable treatment for myasthenia gravis, Zilbrysq, wins Korean approval – KBR

November 22, 2024

Subcutaneous Efgartigimod Demonstrates Efficacy, Safety in Seronegative Myasthenia Gravis

Overall, subcutaneous efgartigimod was safe and effective in patients with seropositive MG, demonstrated by consistent improvements in Myasthenia Gravis-Activites of Daily Living.

November 22, 2024

Study Details of Phase 2 KYSA-6 Trial of CAR-T Therapy in Myasthenia Gravis Presented

The multicenter, 24-week study will feature 20 patients with MG, testing changes on MG-ADL as well as several other secondary outcomes, including patient-reported assessments.

November 21, 2024

The subtlety of my MG symptoms made diagnosis a challenge – Myasthenia Gravis News